# Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT04545762** · PHASE1 · RECRUITING · sponsor: **C. Babis Andreadis** · enrollment: 36 (estimated)

## Conditions studied

- Refractory Non-Hodgkin Lymphoma
- Burkitt Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Small Lymphocytic Lymphoma
- Transformed Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** anti-CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT04545762
- **Lead sponsor:** C. Babis Andreadis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-11
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04545762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04545762, "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04545762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*